林业发展局批准现代公司为18-59岁处于危险中的成年人接种的RSV疫苗,扩大了先前的核准范围。 FDA approves Moderna's RSV vaccine for adults aged 18-59 at risk, expanding previous approval.

林业发展局已经批准为18-59岁成年人接种现代抗逆转录病毒疫苗(mRESVIA),这些成人患RSV疾病的风险增加,并扩大了对60岁及60岁以上成人的初步批准范围。 The FDA has approved Moderna's RSV vaccine, mRESVIA, for adults aged 18-59 at increased risk for RSV disease, expanding its initial approval for those 60 and older. 发现该疫苗在预防严重的与RSV有关的呼吸道问题方面是安全和有效的。 The vaccine was found to be safe and effective in preventing severe RSV-related respiratory issues. 常见副作用包括注射现场疼痛、疲劳、头痛、肌肉疼痛和关节疼痛。 Common side effects include pain at the injection site, fatigue, headache, muscle pain, and joint pain. 它将在即将到来的呼吸道病毒季节提供。 It will be available for the upcoming respiratory virus season.